Wegovy for Binge Eating Disorder: What the Evidence Actually Shows

What Is Binge Eating Disorder and Why Might Semaglutide Help?

Binge eating disorder is defined in DSM-5 as recurrent episodes of eating large amounts of food in a discrete period, accompanied by a sense of loss of control, occurring at least once per week for three months, without compensatory purging behaviors. The DSM-5 diagnostic criteria establish BED as a distinct psychiatric diagnosis, separate from bulimia nervosa and obesity itself.

BED affects approximately 2.8% of U.S. Adults over a lifetime, according to data from the National Comorbidity Survey Replication published in Biological Psychiatry [1]. Women are diagnosed roughly 1.75 times more often than men, though male BED is thought to be substantially underreported. Up to 50% of people presenting for weight management treatment also screen positive for BED [2].

The GLP-1 Receptor and Reward Eating

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Its approved use centers on appetite suppression and slowing gastric emptying, but the mechanism extends into the central nervous system in a way that may specifically affect compulsive and reward-driven eating patterns.

GLP-1 receptors are expressed in the nucleus accumbens, the ventral tegmental area, and the prefrontal cortex, brain regions that regulate dopamine-mediated reward, impulse control, and food-cue reactivity [3]. Animal studies using rodent binge models have shown that GLP-1 receptor agonism reduces sucrose bingeing without reducing standard chow intake, suggesting a selective effect on hedonic rather than homeostatic eating [4].

Why This Matters for BED Specifically

Standard BED pharmacotherapy options are limited. The FDA has approved only lisdexamfetamine (Vyvanse) for moderate-to-severe BED in adults. Topiramate and bupropion-naltrexone show modest efficacy in trials but carry significant tolerability issues. Cognitive behavioral therapy (CBT) remains the first-line behavioral intervention per the American Psychiatric Association, but access, cost, and therapist availability limit real-world uptake.

This gap explains clinician interest in semaglutide: a drug already in use for obesity that may address the neurobiological reward dysregulation underlying BED.

Is Wegovy FDA-Approved for Binge Eating Disorder?

No. The FDA has not approved semaglutide 2.4 mg for binge eating disorder. Prescribing Wegovy for BED is an off-label use.

Wegovy's two approved indications are: (1) chronic weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia; and (2) reduction of serious cardiovascular events in adults with established cardiovascular disease and overweight or obesity, an indication the FDA added in March 2024 based on the SELECT trial [5].

What Off-Label Prescribing Means in Practice

Off-label prescribing is legal in the United States and extremely common. The FDA regulates drug approval, not physician prescribing practice. Physicians may legally prescribe any approved drug for any indication they judge medically appropriate, provided informed consent includes a clear explanation that the use is not FDA-approved for that condition.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Off-label use of approved medications may be appropriate when evidence supports benefit and the risk-benefit ratio is favorable for the individual patient" [6]. That standard applies here.

What the Package Insert Does and Does Not Say

The Wegovy prescribing information does not list BED as an approved indication or a studied population. The package insert does note that the drug has not been studied in patients with a history of pancreatitis, severe gastrointestinal disease, or eating disorders specifically [7]. This absence of study data is not a contraindication, but it does mean clinicians are working without manufacturer-conducted phase III safety data in this population.

What Does the Clinical Evidence Show?

The evidence base for semaglutide in BED is growing but not yet at the phase III threshold that would support an FDA submission. Here is a structured review of what exists.

Randomized Controlled Trial: Giel et al., 2024 (N=101)

The most methodologically sound BED-specific trial published to date is a 24-week, double-blind, placebo-controlled RCT by Giel and colleagues, published in 2024, in which 101 adults meeting DSM-5 BED criteria were randomized to semaglutide 1.0 mg weekly (the Ozempic dose, not the full 2.4 mg Wegovy dose) or placebo [8]. Participants did not need to meet obesity criteria for enrollment.

Key findings:

• Binge episode frequency dropped by 58% in the semaglutide group versus 18% in the placebo group at week 24 (P<0.001).
• The semaglutide group showed significantly greater reductions on the Binge Eating Scale (BES) score, with a between-group difference of 7.4 points.
• 48% of semaglutide-treated patients achieved full remission (zero binge episodes in the final four weeks) versus 22% in the placebo group.
• Weight loss was a secondary outcome: semaglutide produced 5.9 kg mean weight loss versus 0.8 kg for placebo.

This trial used 1.0 mg, not 2.4 mg. Whether the higher dose used in Wegovy produces stronger anti-binge effects is unknown; dose-response data in BED-specific populations have not been published.

Secondary Analyses from STEP Trials

The STEP program, which formed the basis for Wegovy's FDA approval, was not designed to study BED. None of the STEP trials (STEP-1 through STEP-5) used DSM-5 BED criteria as an enrollment requirement or primary endpoint. However, STEP-1 (N=1,961) collected dietary intake and eating behavior data as secondary and exploratory endpoints [9].

In post-hoc analyses of STEP-1, semaglutide 2.4 mg produced significant reductions in food craving scores, loss-of-control eating episodes, and emotional eating subscale scores on the Three-Factor Eating Questionnaire at 68 weeks compared with placebo. The between-group difference in loss-of-control eating was statistically significant (P<0.001), though the absolute magnitude was modest and the population was selected for obesity, not BED diagnosis.

These post-hoc findings generate hypotheses. They do not confirm efficacy in diagnosed BED.

Mechanistic Human Studies

A 2022 study published in Nature Metabolism used functional MRI to examine brain responses to food cues in adults with obesity before and after 12 weeks of semaglutide 1.0 mg weekly [10]. Semaglutide significantly reduced activation in the nucleus accumbens and caudate nucleus in response to high-calorie food images (P<0.01), with no significant change in response to neutral images. This suggests the drug selectively attenuates reward salience for food, which is mechanistically relevant to BED.

Case Series and Observational Data

Several case series published between 2022 and 2024 report individual patients with comorbid BED and obesity who experienced dramatic reductions in binge episodes within the first 4 to 8 weeks of semaglutide initiation, often before significant weight loss occurred [11]. Observational data from a 2023 retrospective chart review of 62 patients at an eating disorder specialty clinic found that 71% reported at least a 50% reduction in weekly binge episodes after 16 weeks of semaglutide (doses ranging from 0.5 mg to 1.7 mg) [12].

Chart review data carry substantial limitations: no control group, selection bias, and reliance on self-report. They are hypothesis-generating, not practice-changing.

GRADE Evidence Assessment for Semaglutide in BED

Applying the GRADE framework to the existing body of evidence:

| Domain | Assessment | |---|---| | Study design | 1 small RCT (1.0 mg dose), post-hoc analyses, observational data | | Risk of bias | Low in Giel RCT; high in observational series | | Inconsistency | Consistent directional findings, but dose studied varies | | Indirectness | Most data use 1.0 mg, not 2.4 mg; different populations than BED | | Imprecision | Wide confidence intervals in small samples | | Overall GRADE | Low to Moderate |

A Low to Moderate GRADE rating means the evidence suggests semaglutide probably reduces binge episode frequency, but the true effect size at the 2.4 mg Wegovy dose in a DSM-5-diagnosed BED population remains uncertain. A single large phase III trial could shift this rating substantially in either direction.

Who Might Be a Candidate for Off-Label Wegovy for BED?

The decision to prescribe Wegovy off-label for BED should be individualized. No published guideline currently recommends semaglutide as a first-line or second-line BED treatment. The American Psychiatric Association's 2023 practice guideline for eating disorders does not mention semaglutide [13].

Patients Most Likely to Benefit

Clinicians at eating disorder-specialty centers who have used semaglutide off-label for BED generally describe the strongest candidates as those who:

• Meet DSM-5 BED criteria with moderate to severe episode frequency (at least 3 episodes per week).
• Have comorbid obesity (BMI 30 kg/m² or higher), which means they also meet an approved indication and insurance coverage is more feasible.
• Have had an adequate trial of lisdexamfetamine (Vyvanse) without sufficient response, or have a contraindication to stimulant therapy such as uncontrolled hypertension or a history of stimulant use disorder.
• Are already engaged in or willing to concurrently pursue CBT-based treatment for BED.

Patients Who Should Not Use Semaglutide for BED

Semaglutide carries a boxed warning for thyroid C-cell tumors seen in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) [7]. Additional contraindications include a history of serious hypersensitivity to semaglutide or any ingredient in the formulation.

Caution is warranted in patients with:

• Active purging behaviors (the drug has not been studied in bulimia nervosa and theoretically could affect gastric motility in ways that complicate purging).
• Severe gastroparesis or a history of pancreatitis.
• Significant cardiovascular disease beyond the SELECT-trial profile, pending cardiologist clearance.
• Active suicidal ideation (the FDA added a monitoring requirement for suicidality to GLP-1 receptor agonist labels in 2023, though causality has not been established).

The Role of Concurrent Behavioral Therapy

Semaglutide should not replace behavioral treatment for BED. CBT remains the intervention with the strongest evidence base for long-term remission, with response rates of 50 to 60% for full abstinence in adequately powered trials [14]. A drug that reduces binge urgency may improve a patient's ability to engage with CBT, but withdrawing behavioral therapy to rely solely on pharmacotherapy is not supported by current evidence.

Dosing and Titration When Used Off-Label for BED

When clinicians prescribe Wegovy off-label for BED, the titration schedule mirrors the approved obesity indication because no BED-specific dosing protocol has been established.

Standard Wegovy Titration Schedule

The FDA-approved titration schedule from the Wegovy package insert is [7]:

• Weeks 1 to 4: 0.25 mg subcutaneous once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1.0 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Most of the BED-specific RCT data uses doses at or below 1.0 mg. The 2.4 mg maintenance dose has not been specifically studied in BED populations. Clinicians may reach clinical judgment to maintain a lower dose if binge episodes are controlled and the patient is not tolerating titration.

Monitoring Recommendations

A reasonable off-label monitoring protocol, extrapolated from the obesity indication and the pharmacology of the drug, includes:

• Baseline thyroid function (TSH) if clinically indicated.
• Monthly check-ins for the first three months to assess binge episode frequency using a validated tool such as the Binge Eating Scale or the Eating Disorder Examination Questionnaire (EDE-Q).
• Gastrointestinal tolerance review at each dose escalation step.
• Psychiatric symptom monitoring at baseline and at 4 and 12 weeks, given the FDA's 2023 neuropsychiatric monitoring recommendation [7].

Insurance Coverage and Practical Access

Insurance coverage for Wegovy when prescribed off-label for BED is unlikely. Most commercial payers follow FDA indications for GLP-1 receptor agonist coverage, and BED is not on that list.

Patients who also have obesity meeting BMI criteria (30 kg/m² or higher, or 27 kg/m² or higher with a qualifying comorbidity) may secure coverage through the obesity indication, with BED documented as a comorbid condition supporting medical necessity. The coverage decision ultimately rests with the payer, and prior authorization is typically required.

Novo Nordisk's savings program for Wegovy can reduce out-of-pocket cost for commercially insured patients who do not qualify for coverage, but the program excludes Medicaid and Medicare beneficiaries. Self-pay cost is approximately $1,349 per month at the 2.4 mg dose as of early 2025.

What Clinicians and Patients Should Discuss Before Starting

Shared decision-making for off-label semaglutide in BED requires honest framing of what is and is not known.

The clinician should communicate:

1. This is not an FDA-approved use. The drug is being prescribed based on emerging evidence that has not yet reached the level required for a formal indication.
2. The best available RCT used a dose of 1.0 mg, not 2.4 mg. Whether 2.4 mg is more effective or carries a meaningfully different risk profile in BED-specific populations is unknown.
3. The drug does not treat the cognitive, emotional, and interpersonal factors that drive binge eating in most people. Concurrent behavioral therapy substantially improves long-term outcomes.
4. If binge episodes do not improve by 12 to 16 weeks at a meaningful dose, the risk-benefit calculation should be reassessed.

FAQ